Novartis to buy breast cancer drug candidate from Synnovation
Novartis is set to acquire a promising breast cancer drug candidate from Synnovation Therapeutics in a deal worth up to $3 billion, strengthening its oncology pipeline. The experimental therapy targets HR-positive/HER2-negative breast cancer using a next-generation PI3Kα inhibition approach.
Ludwig Burger/Reuters
March 20, 2026
FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020.
Arnd Wiegmann/Reuters
Novartis NOVN.S said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development achievements.
The experimental drug belongs to the class of selective PI3Kα inhibitors, a new approach for the treatment of a type of breast cancer known as HR positive/HER2 negative and potentially other solid tumours.
-Ludwig Burger/Reuters
TOP HEALTH STORIES
ANALYSIS: Why the WHO should declare climate change a public health emergency
Airline groups raises concerns over US CDC Ebola travel declaration requirements
US estrogen shortage deepens as women seek alternatives to scarce patches
LATEST NEWS
Philippine gov't strengthens ecosystem protection against El Niño threat
EXPLAINER: How could an oil spill off the UAE coast threaten desalination plants?
UN says world is falling behind on ecosystem restoration goals
Paraluman News Publication, Inc.
desk@myparaluman.ph
Tektite Towers (East), Exchange Road
Ortigas Center. San Antonio 1600
City of Pasig, NCR, Philippines
+63284298877
EXPLORE
Editorial Standards and Code of Ethics
Privacy Policy
User Policy
COMMUNITY
Contributor and Campus Voices Terms
Advertise with Paraluman News
ACCOUNTABILITY & SAFETY
Submit a Claim for Fact-Checking
© 2026 Paraluman News Publication